Skip to main content
. 2014 Nov 6;9(11):e112201. doi: 10.1371/journal.pone.0112201

Figure 2. Kaplan-Meier plots for progression free survival for patients with KRAS wild type (19 statin-users and 145 nonusers) and KRAS mutant (16 statin-users and 83 nonusers) tumors treated with capecitabine, oxaliplatin, bevacizumab and cetuximab.

Figure 2